Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akio Suzuki

Showing results (161-170 of 203) with videos related to

Pageof 21
Sort By:
Medical Oncology (Northwood, London, England)|June 5, 2019
High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapyYunami Yamada, Hironori Fujii, Koichi Ohata, et al.
Journal of Clinical Pharmacy and Therapeutics|January 4, 2021
Albumin-bilirubin score for predicting neuropsychiatric symptoms in patients receiving ifosfamide-based chemotherapyShinya Shimizu, Yuichi Hayashi, Shohei Nishida, et al.
International Journal of Clinical Practice|September 4, 2021
Clinical impact of monitoring frequency per day as a prospective audit and feedback strategy for patients receiving antimicrobial agents by injectionAyasa Goto-Fujibayashi, Takashi Niwa, Jun Yonetamari, et al.
Gynecologic Oncology|January 14, 2020
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II studyHirotoshi Iihara, Mototsugu Shimokawa, Yoh Hayasaki, et al.
International Journal of Cardiology|July 1, 2025
Changes in syndecan-1 concentration in the coronary sinus immediately after cardiac reperfusion reflect postoperative myocardial injuryTakayoshi Kato, Keiko Suzuki, Hiromu Kawashima, et al.
Gut Microbes|August 1, 2025
Pyruvate-GPR31 axis induces LysoDC dendrite protrusion to M-cell pockets for effective immune responsesKatsuhiro Nakanishi, Takayuki Ajiro, Kaito Yukishima, et al.
Anticancer Research|March 31, 2021
Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line TherapyYukina Sato, Hirotoshi Iihara, Motohiko Kinomura, et al.
BMC Cancer|July 20, 2021
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trialsSenri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, et al.
International Journal of Clinical Practice|February 28, 2019
Clinical impact of matrix-assisted laser desorption ionization-time of flight mass spectrometry combined with antimicrobial stewardship interventions in patients with bloodstream infections in a Japanese tertiary hospitalTakashi Niwa, Jun Yonetamari, Nozomi Hayama, et al.
BMC Cancer|March 24, 2022
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysisSenri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, et al.
Pageof 21

Showing results (161-170 of 203) with videos related to

Sort By:
Pageof 21
Medical Oncology (Northwood, London, England)|June 5, 2019
High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapyYunami Yamada, Hironori Fujii, Koichi Ohata, et al.
Journal of Clinical Pharmacy and Therapeutics|January 4, 2021
Albumin-bilirubin score for predicting neuropsychiatric symptoms in patients receiving ifosfamide-based chemotherapyShinya Shimizu, Yuichi Hayashi, Shohei Nishida, et al.
International Journal of Clinical Practice|September 4, 2021
Clinical impact of monitoring frequency per day as a prospective audit and feedback strategy for patients receiving antimicrobial agents by injectionAyasa Goto-Fujibayashi, Takashi Niwa, Jun Yonetamari, et al.
Gynecologic Oncology|January 14, 2020
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II studyHirotoshi Iihara, Mototsugu Shimokawa, Yoh Hayasaki, et al.
International Journal of Cardiology|July 1, 2025
Changes in syndecan-1 concentration in the coronary sinus immediately after cardiac reperfusion reflect postoperative myocardial injuryTakayoshi Kato, Keiko Suzuki, Hiromu Kawashima, et al.
Gut Microbes|August 1, 2025
Pyruvate-GPR31 axis induces LysoDC dendrite protrusion to M-cell pockets for effective immune responsesKatsuhiro Nakanishi, Takayuki Ajiro, Kaito Yukishima, et al.
Anticancer Research|March 31, 2021
Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line TherapyYukina Sato, Hirotoshi Iihara, Motohiko Kinomura, et al.
BMC Cancer|July 20, 2021
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trialsSenri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, et al.
International Journal of Clinical Practice|February 28, 2019
Clinical impact of matrix-assisted laser desorption ionization-time of flight mass spectrometry combined with antimicrobial stewardship interventions in patients with bloodstream infections in a Japanese tertiary hospitalTakashi Niwa, Jun Yonetamari, Nozomi Hayama, et al.
BMC Cancer|March 24, 2022
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysisSenri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, et al.
Pageof 21